References
1. Walsh CS. 2015. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol 137(2):343-350. doi: 10.1016/j.ygyno.2015.02.017.
2. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523-533. doi: 10.1056/NEJMoa1706450.
3. Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. 2020. PARP inhibitor resistance: The underlying mechanisms and clinical implications. Mol Cancer 19(1):107. doi: 10.1186/s12943-020-01227-0.
4. Waks AG, Cohen O, Kochupurakkal B, et al. 2020. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol 31(5):590-598. doi: 10.1016/j.annonc.2020.02.008.
5. Pan JN, Lei L, Ye WW, Wang XJ, Cao WM. 2021. BRCA1 reversion mutation confers resistance to Olaparib and camrelizumab in a patient with breast cancer liver metastasis. J Breast Cancer 24(5):474-480. doi: 10.4048/jbc.2021.24.e39.
6. Gornstein EL, Sandefur S, Chung JH, et al. 2018. BRCA2 reversion mutation associated with acquired resistance to Olaparib in estrogen receptor-positive breast cancer detected by genomic profiling of tissue and liquid biopsy. Clin Breast Cancer 18(2):184-188. doi: 10.1016/j.clbc.2017.12.010.
7. Tobalina L, Armenia J, Irving E, O’Connor MJ, Forment JV. 2021. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol 32(1):103-112. doi: 10.1016/j.annonc.2020.10.470.
8. Pettitt SJ, Frankum JR, Punta M, et al. 2020. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov 10(10):1475-1488. doi: 10.1158/2159-8290.CD-19-1485.
9. Weigelt B, Comino-Méndez I, de Bruijn I, et al. 2017. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res 23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544.
10. Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep 17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.
11. Dréan A, Williamson CT, Brough R, et al. 2017. Modeling therapy resistance in BRCA1/2-mutant cancers. Mol Cancer Ther 16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098.